Company Overview
About Nephrogen
Nephrogen is a San Francisco-based preclinical gene therapy company — backed by Y Combinator (W20) with $1.1 million in total funding including $775,000 raised to date plus a $325,000 NIH SBIR grant, and currently raising a $4 million seed round with support from StartX and 2048 Ventures — developing curative gene therapies for kidney diseases, with polycystic kidney disease (PKD) as the lead program targeting the 600,000 Americans with the autosomal dominant PKD subtype, an inherited kidney cyst disorder with no disease-modifying treatments that currently progresses to end-stage renal disease requiring dialysis or transplant in the majority of patients. Founded by researchers with combined expertise in AI-driven drug discovery, genetic engineering, and nephrology, Nephrogen applies AI target identification and gene therapy delivery to the largest category of rare inherited kidney diseases.
Business Model & Competitive Advantage
Nephrogen's gene therapy approach to PKD addresses the root cause rather than managing progression: PKD is caused by mutations in the PKD1 or PKD2 genes that disrupt polycystin protein function in kidney tubule cells — causing abnormal fluid-filled cyst growth that progressively replaces normal kidney tissue over decades. Existing therapies (tolvaptan, the only FDA-approved treatment) slow but do not halt PKD progression and carry liver toxicity risks requiring regular monitoring. Nephrogen's gene therapy program uses viral vectors to deliver functional copies of the mutated gene or gene-silencing constructs to kidney cells — targeting the molecular defect rather than downstream cyst growth pathways. The AI drug discovery integration (computational models identifying optimal delivery vectors, expression cassette designs, and dosing regimens from preclinical data) accelerates the iterative optimization that gene therapy development requires. The NIH SBIR grant (Phase I research funding from the National Institute of Diabetes and Digestive and Kidney Diseases) validates the scientific merit of Nephrogen's approach.
Competitive Landscape 2025–2026
In 2025, Nephrogen competes in the gene therapy, rare kidney disease, and genetic medicine market with Passage Bio (rare neurological gene therapy, $216M raised), CRISPR Therapeutics (NASDAQ: CRSP, gene editing, multiple programs), and Oricell Therapeutics (kidney-focused gene therapy) for preclinical PKD gene therapy program development and seed investment in genetic kidney disease. The PKD Foundation estimates 600,000 Americans and 12.5 million people worldwide have ADPKD — making it one of the most common inherited kidney diseases with a large patient population relative to other rare disease targets. Nephrogen's $4 million seed raise target reflects the preclinical stage milestone funding needed to generate the in vivo efficacy and safety data required for IND-enabling studies. The 2025 strategy focuses on demonstrating proof-of-concept gene therapy efficacy in PKD mouse models, building the delivery platform for kidney-targeted gene therapy vectors, and establishing the manufacturing process development foundation.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Nephrogen is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Hellohive
Hellohive is a New York City-based virtual recruiting platform specializing in diverse early-career talent — backed with $9 million in total funding including a $3.4 million Series A in February 2024
Hims & Hers
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for condi
Doximity
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic
Headspace
Headspace is a mental wellness company founded in 2010 by Andy Puddicombe and Rich Pierson that has grown into one of the most widely used mindfulness and meditation apps globally. The platform offers
Zocdoc
Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati
Noom
Noom is a digital health company founded in 2008 that has grown into one of the most widely used weight management platforms, serving millions of members through its psychology-driven approach to beha
Compare Nephrogen with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Nephrogen? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Nephrogen Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Nephrogen vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →